Ligand-based drug design methodologies in drug discovery process: An overview

Current Drug Discovery Technologies

Volumn 3, Issue 3, 2006, Pages 155-165

  Bacilieri, Magdalena ^a   Moro, Stefano ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Chemometrics; Drug discovery; Ligand based drug design; Quantitative structure activity relationship (QSAR)

Indexed keywords

CORTICOSTEROID BINDING GLOBULIN RECEPTOR; CORTICOSTEROID RECEPTOR; LIGAND; STEROID; UNCLASSIFIED DRUG;

COMPARATIVE MOLECULAR FIELD ANALYSIS; DATA BASE; DRUG DESIGN; DRUG RESEARCH; DRUG STRUCTURE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

DRUG DESIGN; LIGANDS; MODELS, THEORETICAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 33947258002     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016306780136781     Document Type: Review

References (81)

1. Gasteiger J., Engel T.: Chemoinformatics. Wiley - VCH GmbhH & Co. KGaA, Weinheim (2003).
2. Hansh C., Leo A.: Exploring QSAR. Fundamentals and Applications in Chemistry and Biology. American Chemical Society. Washington, DC, (1995).
3. Stahura Fl, Bajorath J.: New methodologies for ligand-based virtual screening. Curr. Pharm. Des. 11, 1189-1202, (2005).
4. Pozzan A.: Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery. Curr. Pharm. Des. 12, 2099-2110, (2006).
5. Xue L., Bajorath J.: Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening. Comb. Chem. High Throughput Screen. 3, 363-372, (2000).
6. Kubini H.: Comparative molecular field analysis (CoMFA). The encyclopaedia of computational chemistry. Wiley & Sons, 448-460 (1998).
7. Cramer R.D., Patterson D.E., Bunce J.D.: Comparative Molecular Field Analysis (CoMFA) 1.Effects of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110, 5959-5967, (1988).
8. Wildman S.A., Crippen G.M.: Three-dimensional molecular descriptors and a novel QSAR method. J. Mol. Graph. Model. 21, 161-170, (2002).
9. 3 analogues for vitamin D receptor. Steroids 71, 510-527, (2006).
10. Peters MB., Raha K., Merz KM Jr.: Quantum mechanics in structure-based drug design. Curr. Opin. Drug Discov. Devel. 9, 370-379, (2006).
11. O'brien S.E., Popelier P.L.A.: Quantum molecular similarity. 3. QTMS descriptors. J. Chem. Inf. Comput. Sci. 41, 764-775, (2001).
12. Popelier P.L.A., Smith P.J.: QSAR models based on quantum topological molecular similarity. Europ. J. Med. Chem. 41, 862-872, (2006).
13. Arulmozhiraja S., Morita M.: Structure- Activity Relationships for the toxicity of polychlorinated dibenzofurans: approach through density functional theory-based descriptors. Chem. Res. Toxicol. 17, 348-356, (2004).
14. Wold S., Sjjostrom M., Eriksson L.: Partial Least Squares Projections to Latent Structures (PLS) in chemistry. The encyclopaedia of computational chemistry. Wiley & Sons, 2006-2022 (1998).
15. Leach A.R., Gillet V.J.: An introduction in chemoinformatics. Kluwer Academic Publishers (2003).
16. Erikkson L., Jhoansson E., Kettaneh-Wold N., Wold S.: Multi and Megavariate data analysis. Principles and applications. Umetrics Academy (2001).
17. Koza J.R.: Genetic Programming: on the programming of computers by means of natural selection. MIT press, Cambridge (1992).
18. Zupan J.: Introduction to artificial neural network (ANN) methods: what they are and how to use them. Acta Chim. Slov. 41, 327352, (1994).
19. Gasteiger J., Teckentrup A., Terfloth L., Spycher S.: Neural networks as data mining tools in drug design. J. Phys. Org. Chem. 16, 232-245, (2003).
20. Mitchell T.M.: Machine Learning. Mc Graw-Hill (1997).
21. Russel S., Norvig P.: Artificial intelligence, a modern approach. Artificial intelligence Series. Prentice Hall (2003).
22. Livingstone D., Manallack D.: Neural Networks in 3D QSAR. QSAR 22, 510-518, (2003).
23. Soler M.M., Gimenez F.P., Garcia-March F.J., Salabert-Salvador M.T., Diaz-Villanueva W., Castro-Bleda M.J.: Drugs and nondrugs: an effective discrimination with topological methods and artificial neural networks. J. Chem. Comput. Sci. 43, 1688-1702, (2003).
24. Czerminski R., Yarsi A., Hartsough D.: Use of Support Vector Machine in pattern classification: application to QSAR studies. QSAR 20, 227-240, (2001).
25. Norinder U.: Support Vector Machine models in drug design: applications to drug transport processes and QSAR using simplex optimisations and variable selection. Neurocomputing 55, 337-346, (2003).
26. Warmuth M., Liao J., Ratsch G., Mathieson M., Putta S., Lammen C.: Active learning with Support Vector Machines in the drug discovery process. J. Chem. Comput. Sci. 43, 667-673, (2003).
27. Hudelson M.G., JonesS J.P.: Line-walking method for predicting the inhibition of P450 drug metabolism. J. Med. Chem. 49, 4367-4373, (2006).
28. Saeh J.C., Lyne P.D., Takasaki B.K., Cosgrove D.A.: Lead hopping using SVM and 3D pharmacophore fingerprints. J. Chem. Comput. Sci. 45, 1122-1133, (2005).
29. 3 receptor antagonist 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives using chemometric tools. Bioorg. Med. Chem. Lett. 15, 3737-3743, (2005).
30. 3 receptor antagonist using FA and GFA techniques. Bioorg. Med. Chem. Lett. 13, 1159-1165, (2005).
31. Singh J., Chuaqui C.E., Boriack-Sjodin P.A., Lee W.C., Pontz T.P., Corbey M.J., Cheung H.K., Arduini R.M., Mead J.N., Newman M.N., Papadatos J.L., Bowes S. et al.: Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFb receptor kinase (TbRI). Bioorg. Med. Chem. Lett. 13, 4355-4359, (2003).
32. Lima P.C., Golbraikh A., Ooloff S., Xiao Y., Tropsha A.: Combinatorial QSAR modelling of P-glycoprotein substrates. J. Chem. Inf. Model. 46, 1245-1254, (2006).
33. Taha M.O., Qandil A.M., Zaki D.D., Aladamen M.A.: Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modelling. Europ. J. Med. Chem. 40, 701-727, (2005).
34. Kraker J.K., Hawkins D.M., Basak S.C., Natarajan R., Mills D.: Quantitative structure activity relationship (QSAR) modelling of juvenile hormone activity comparison of validation procedures. Chem. Int. Lab. Sys. (2006) in press.
35. Kitchen DB, Stahura FL, Bajorath J.: Computational techniques for diversity analysis and compound classification. Mini Rev Med Chem. 4, 1029-1039, (2004).
36. Stahura FL, Bajorath J. Partitioning methods for the identification of active molecules. Curr. Med. Chem. 10, 707-715, (2003).
37. Goldman B.B., Wipke W.T.: Quadratic shape descriptors. 1. Rapid superimposition of dissimilar molecules using geometrically invariant surface descriptors. J. Chem. Inf. Comput. Sci. 40, 644-658, (2000).
38. Nikolova N., Jaworska J.: Approaches to measure chemical similarity - a review. QSAR Comb. Sci. 22, 1006-1026, (2003).
39. Javorska J., Nikolova N., Aldenberg T.: QSAR applicability domain estimation by projection of the training set in descriptor space: a review. ATLA 33, 445-459, (2005).
40. Guha R., Dutta D., Jurs PC., Chen T.: R-NN curves: an intuitive approach to outlier detection using a distance based method. J. Chem. Inf. Model. 46, 1713-1722, (2006).
41. Xu J., Stevenson J.: Drug-like index: a new approach to measure drug-like compounds and their diversity. J. Chem. Inf. Comput. Sci. 40, 1177-1187, (2000).
42. Andrews K.M., Cramer R.D.: Towards general methods of targeted library design: topomer shape similarity searching with diverse structures as queries. J. Med. Chem. 43, 1723-1740, (2000).
43. Putta S., Lemmen C., Beroza P., Greene J.: A novel shape-feature based approach to virtual library screening. J. Chem. Inf. Comput. Sci. 42, 1230-1240, (2002).
44. Mason J.S., Good A.C., Martin E.J.: 3-D pharmacophores in drug discovery. Curr. Pharm. Des. 7, 567-597, (2001).
45. Patel Y., Gillet VJ., Bravi G., Leach Ar.: A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. J. Comp.- Aided Mol. Des. 16, 653-681, (2002).
46. Verli H., Albuquerque M.G., Bicca De Alencastro R., Barriero E.J.: Local intersection volume: a new 3D descriptor applied to develop a 3D-QSAR pharmacophore model for benzodiazepine receptor ligands. Europ. J. Med. Chem. 37, 219-229, (2002).
47. Rennen S., Schneider G.: Fuzzy pharmacophore models from molecular alignment for correlation-vector based virtual screening. J. Med. Chem. 47, 4653-4664, (2004).
48. Klebe G., Abraham U., Mietzner T.: Molecular Similarity Indices in a Comparative Analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 37, 4130-4146, (1994).
49. Robinson D.D., Winn P.J., Lyne P.Dd, Richards G.: Self Organizing Molecular Field Analysis: a tool for structure-activity studies. J. Med. Chem. 42, 573-583, (1999).
50. Polanki J., Walczak B.: The Comparative Molecular Surface Analysis (CoMSA): a novel tool for molecular design. Computer Chem. 24, 615-625, (2000).
51. Lemmen C., Lengauer T.: Computational methods for the structural alignment of molecules. J. Comp. Aided Mol. Des. 14, 215-132, (2000).
52. Mills J.E.J., De Ewsch I.J.P., Perkins T.D.J., Dean P.M.: Slate: a method for the superimposition of flexible ligands. J. Comp. Aided Mol. Des. 15, 81-96, (2001).
53. Labute P., Williams C., Peher M., Sourial E., Schidt J.M.: Flexible alignment of small molecules. J. Med. Chem. 44, 1483-1490, (2001).
54. Arakawa M., Hasegawa K., Funatsu K.: Novel alignment method of small molecules using the Hopfiled Neural Network. J. Chem. Inf. Comput. Sci. 43, 1390-1395, (2003).
55. Arakawa M., Hasegawa K., Funatsu K.: Application of novel molecular alignment method using the Hopfiled Neural Network to 3D-QSAR. J. Chem. Inf. Comput. Sci. 43, 1396-1402, (2003).
56. Gasteiger J., Li X., Rudolph C., Sadovski J., Zupan J.: Representation of Molecular Electrostatic Potential by topological feature maps. J. Am. Chem. Soc. 116, 4608-4620, (1994).
57. Wagener M., Sadovski J., Gasteiger J.: Autocorrelation of molecular surface properties for modeling corticosteroid binding globulin and cytosolic Ah receptor activity by neural networks. J. Am. Chem. Soc. 117, 7769-7778, (1995).
58. Bauknecht H., Zell A., Bayer H., Levi P., Sadowsky J., Gasteiger J.: Locating biologically active compounds in medium-sized heterogeneous datasets by topological autocorrelation vectors: dopamine and benzodiazepine agonists. J. Chem. Inf. Comput. Sci. 36, 1205-13, (1996).
59. Moro S., Bacilieri M., Ferrari C., Spalluto G.: Autocorrelation of molecular electrostatic potential surface properties combined with Partial Least Squares analysis as alternative attractive tool to generate ligand-based 3D-QSARs. Curr. Drug. Disc. Tech. 2, 13-21, (2005).
60. Moro S., Bacilieri M., Cacciari B., Spalluto G.: Autocorrelation of molecular electrostatic potential surface properties combined with partial least squares analysis as new strategy for the prediction of the activity of human A(3) adenosine receptor antagonists. J. Med. Chem. 48, 5698-704, (2005).
61. Silvermann B.D., Platt D.E.: Comparative Molecular Moment Analysis (CoMMA): 3D-QSAR without molecular superimposition. J. Med. Chem. 39, 2129-2140, (1996).
62. Bursi R., Dao T., Van Wijk T., De Gooyer M., Kellenbach E., Verwer P.: Comparative Spectra Analysis (CoSA): spectra as three-dimensional molecular descriptors for prediction of biological activities. J. Chem. Inf. Comput. Sci. 39, 861-867, (1999).
63. Bravi G., Gancia E., Mascagni P., Pegna M., Todeschini R., Zaliani A.: MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: a comparative 3D QSAR study in a series of steroids. J. Comp. Aided. Mol. Des. 11, 79-92, (1997).
64. Gancia E., Bravi G., Mascagni P., Zaliani A.: Global 3D QSAR methods: MS-WHIM and autocorrelation. J. Comp. Aided Mol. Des. 14, 293-306, (2000).
65. Pastor M., Cruciani G., Mclay I., Pickett W., Clementi S.: Grid-Independent Descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. J. Med. Chem. 43, 3233-3243, (2000).
66. Lowis D.R.: HQSAR: a new, highly predictive QSAR technique. Tripos Techn. Notes. 1, 1-17, (1997).
67. Suh M.E., Park S.Y., Lee H.J.: Comparison of QSAR methods (CoMFA, CoMSIA, HQSAR) of anticancer 1-N-substituted imidazoquinoline-4,9-dione derivatives. Bull. Korean Chem. Soc. 23, 417-422, (2002).
68. Klein C.T., Kaiser D., Ecker G.: Topological distance based 3D descriptors for use in QSAR and diversity analysis. J. Chem. Inf. Comput. Sci. 44, 200-209, (2004).
69. Wagener M., Sadovski J., Gasteiger J.: Autocorrelation of molecular surface properties for modeling corticosteroid binding globulin and cytosolic Ah receptor activity by neural networks. J. Am. Chem. Soc. 117, 7769-7778, (1995).
70. Coats E.: The CoMFA steroids as a benchmark dataset for development of 3D QSAR methods. Perspect. Drug. Des. 12-14, 199-213, (1998).
71. Sippl W., Holtje H.D.: Structure-based 3D-QSAR-merging the accuracy of structure-based alignments with the computational efficiently of ligand-based methods. Teochem 503, 31-50, (2000).
72. Sippl W.: Receptor-based 3D-QSAR analysis of estrogen receptor ligands-merging the accuracy of structure-based alignments with the computational efficiently of ligand-based methods. J. Comp. Aided Mol. Des. 14, 559-572, (2000).
73. Sippl W.: Binding affinity prediction of novel estrogen receptor ligands using receptor-based 3D-QSAR methods. Bioorg. Med. Chem. 10, 3741-3755, (2002).
74. Wolohan P., Reicher D.E.: CoMFA and docking study of novel estrogen receptor subtype selective ligands. J. Comp. Aided Mol. Des. 17, 313-328, (2003).
75. Wolohan P., Reicher D.E.: Use of binding energy in comparative molecular field analysis of isoform selective estrogen receptor ligands. J. Mol. Graph. Model. 23, 23-38, (2004).
76. Tsai K.C., Chen S.Y., Liang P.H., Lu I.L., Mahindroo N., Hsieh H.P., Chao Y.S., Liu L, et al.: Discovery of a novel family of SARS-Co protease inhibitors by virtual screening and 3D-QSAR studies. J. Med. Chem. 49, 3485-3495, (2006).
77. Menezes I.R.A., Leitao A., Montanari C.A.: Three dimensional models of non-steroidal ligands: a comparative molecular field analysis. Steroids 71, 417-428, (2006).
78. Brigo A., Mustata G.I., Briggs J.M., Moro S.: Discovery of HIV-1 integrase inhibitors through a novel combination of ligand and structure-based drug design. Med. Chem. 1, 263-175, (2005).
79. Moro S., Braiuca P., Deflorian F., Ferrari C., Pastorin G., Cacciari B., Baraldi P.G., Varani K., et al.: Combined target-based and ligand-based drug design approach as a tool to define 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo [4,3-e] 1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study. J. Med. Chem. 48, 152-162, (2005).
80. Moro S., Deflorian F., Bacilieri M., Spalluto G.: Novel strategies for the design of new potent and selective human A3 adenosine receptor antagonists: an update. Curr. Med. Chem. 13, 763-771, (2006).
81. Moro S., Deflorian F., Bacilieri M., Spalluto G.: Ligand-based homology modelling as attractive tool to inspect GPCR structural plasticity. Curr. Pharm. Des. 12, 2175-2185, (2006).